載入...
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Almost 800,000 new or recurrent strokes occur every year. Atrial fibrillation, the most common cardiac arrhythmia, is a major risk factor for stroke, accounting for 15-20% of ischemic strokes. Apixaban is a direct inhibitor of Factor Xa that was approved in December 2012 by the US Food and Drug Admi...
Na minha lista:
| 發表在: | Curr Cardiol Rev |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Bentham Science Publishers
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5324317/ https://ncbi.nlm.nih.gov/pubmed/27450450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1573403X12666160720092024 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|